These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R Hum Gene Ther; 2011 Nov; 22(11):1343-53. PubMed ID: 21366404 [TBL] [Abstract][Full Text] [Related]
7. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Diaz RM; Galivo F; Kottke T; Wongthida P; Qiao J; Thompson J; Valdes M; Barber G; Vile RG Cancer Res; 2007 Mar; 67(6):2840-8. PubMed ID: 17363607 [TBL] [Abstract][Full Text] [Related]
9. Investigating Macrophages Plasticity Following Tumour-Immune Interactions During Oncolytic Therapies. Eftimie R; Eftimie G Acta Biotheor; 2019 Dec; 67(4):321-359. PubMed ID: 31410657 [TBL] [Abstract][Full Text] [Related]
10. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Rommelfanger DM; Wongthida P; Diaz RM; Kaluza KM; Thompson JM; Kottke TJ; Vile RG Cancer Res; 2012 Sep; 72(18):4753-64. PubMed ID: 22836753 [TBL] [Abstract][Full Text] [Related]
11. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment. Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741 [TBL] [Abstract][Full Text] [Related]